Literature DB >> 31311716

Acquired Hemophilia A After Nivolumab Therapy in a Patient With Metastatic Squamous Cell Carcinoma of the Lung Successfully Managed With Rituximab.

Hamza N Gokozan1, Judah D Friedman2, Alvin H Schmaier2, Katharine A Downes1, Lisa A Farah3, Hollie M Reeves4.   

Abstract

Entities:  

Keywords:  Acquired hemophilia A; Bethesda assay; Immunotherapy; Nivolumab; PD-1

Mesh：

Substances：

Year:  2019        PMID： 31311716     DOI： 10.1016/j.cllc.2019.06.022

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN： 1525-7304            Impact factor:   4.785


× No keyword cloud information.
  4 in total

1.  Increased Incidence of Venous Thromboembolism with Cancer Immunotherapy.

Authors:  Joanna Roopkumar; Shadi Swaidani; Ann S Kim; Bicky Thapa; Lorenzo Gervaso; Brian P Hobbs; Wei Wei; Tyler J Alban; Pauline Funchain; Suman Kundu; Naseer Sangwan; Patricia Rayman; Paul G Pavicic; C Marcela Diaz-Montero; John Barnard; Keith R McCrae; Alok A Khorana
Journal:  Med (N Y)       Date:  2021-03-12

2.  Pembrolizumab-induced Pure Red Cell Aplasia Successfully Treated with Intravenous Immunoglobulin.

Authors:  Atsushi Isoda; Yuri Miyazawa; Kenichi Tahara; Masahiro Mihara; Akio Saito; Morio Matsumoto; Morio Sawamura
Journal:  Intern Med       Date:  2020-05-08       Impact factor: 1.271

3.  A Case of Acquired Factor V Inhibitor Following Nivolumab Administration.

Authors:  Wataru Kida; Muneo Nakaya; Akiko Ito; Yasuji Kozai; Masato Bingo
Journal:  Cureus       Date:  2022-01-27

4.  Acquired Hemophilia as a Paraneoplastic Syndrome in a Patient With Small Cell Lung Carcinoma.

Authors:  James F Lyon; Alina Basnet
Journal:  Cureus       Date:  2022-04-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.